Literature DB >> 12355004

Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases.

David K W Yeung1, Wei-Tse Yang, Gary M K Tse.   

Abstract

PURPOSE: To assess the relationship between breast cancer subtypes and choline detection by using in vivo proton magnetic resonance (MR) spectroscopy and to assess the feasibility of proton MR spectroscopy in the study of axillary lymph node metastases.
MATERIALS AND METHODS: Breast and lymph node MR spectroscopy of lesions identified at contrast material-enhanced MR imaging was performed in 39 patients with breast cancer. Spectroscopic and histopathologic findings were determined and compared. The sensitivity, specificity, and accuracy of the MR spectroscopic technique in the detection of axillary lymph node metastases were determined.
RESULTS: There were four cases of ductal carcinoma in situ (DCIS) and 34 invasive carcinomas, including three with an extensive in situ component. Twenty-six breast lesions were positive for choline at MR spectroscopy; nine, negative; and three, failed cases (ie, determination of positive or negative for choline could not be made). No data were available for one lesion. Four of the nine negative findings were DCIS; three, infiltrating ductal carcinoma (IDC) with an extensive in situ component; and two, IDC. Fourteen axillary lymph nodes were positive for choline; 17, negative; and four, failed cases. No data were available for four nodes. Comparison of the preliminary diagnostic indexes of the MR spectroscopic technique with the ultrasonographically guided fine-needle aspiration biopsy findings in lymph nodes revealed a sensitivity of 82%, specificity of 100%, and accuracy of 90%.
CONCLUSION: Choline is consistently detected in IDC. DCIS and IDC with an extensive in situ component are likely to be negative for choline at MR spectroscopy. In vivo proton MR spectroscopy of axillary lymph nodes in patients with breast cancer is feasible and has encouraging preliminary results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355004     DOI: 10.1148/radiol.2243011519

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

1.  The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging.

Authors:  M D Dorrius; R M Pijnappel; M C van der Weide Jansen; L Jansen; P Kappert; M Oudkerk; P E Sijens
Journal:  Eur Radiol       Date:  2011-11-11       Impact factor: 5.315

2.  [Non-invasive imaging modalities for preoperative axillary lymph node staging in patients with breast cancer].

Authors:  K Wasser; A Schnitzer; J Brade; S O Schoenberg
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

Review 3.  Advances in breast imaging: magnetic resonance imaging.

Authors:  Lia Bartella; Elizabeth A Morris
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

4.  Current Status and New Developments in Breast MRI.

Authors:  Katja C Siegmann; Bernhard Krämer; Claus Claussen
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

Review 5.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

6.  Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS.

Authors:  J-H Chen; R S Mehta; H-M Baek; K Nie; H Liu; M Q Lin; H J Yu; O Nalcioglu; M-Y Su
Journal:  NMR Biomed       Date:  2010-09-22       Impact factor: 4.044

Review 7.  MR spectroscopy of the breast.

Authors:  F Sardanelli; A Fausto; F Podo
Journal:  Radiol Med       Date:  2008-02-25       Impact factor: 3.469

8.  MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.

Authors:  Patricia R Geraghty; Maurice A A J van den Bosch; Daniel M Spielman; Sandeep Hunjan; Robyn L Birdwell; Katherine J Fong; Lara A Stables; Marowan Zakhour; Robert J Herfkens; Debra M Ikeda
Journal:  Breast J       Date:  2008-10-13       Impact factor: 2.431

9.  Diagnostic value of breast proton magnetic resonance spectroscopy at 1.5T in different histopathological types.

Authors:  Hyeon-Man Baek
Journal:  ScientificWorldJournal       Date:  2012-05-01

Review 10.  Monitoring therapeutic efficacy in breast carcinomas.

Authors:  Anne A Tardivon; Liliane Ollivier; Carl El Khoury; Fabienne Thibault
Journal:  Eur Radiol       Date:  2006-05-30       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.